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Abstract 
Activation of the poly(ADP-ribose) polymerase after oxidative damage is implicated in different responses of the cells, for example, 
cell recovery after sublethal damage or cell death after lethal damage. However, the extent and mechanism of involvement of the enzyme 
in these two processes appear to be different. Inhibitors of this polymerase, such as benzamides, which do not completely inhibit PARP 
have been shown to protect the cells from killing by massive oxidant damage, could neither reduce the cellular recovery after mild 
oxidant damage nor completely inhibit DNA repair in vitro. We report here that 1,5-dihydroxyisoquinoline, which was earlier shown to 
be a strong inhibitor of this polymerase in vitro, is also its potent inhibitor in vivo. Using sensitive techniques for measuring low levels of 
cellular poly(ADP-ribose) polymer, we show that this inhibitor can completely abolish oxidant-induced activation of the polymerase in 
C3HlOTl/2 cells. We show that only a minor fraction of the poly(ADP-ribose) polymerase activity is sufficient in cellular recovery after 
sublethal oxidant damage. We also demonstrate that cells are unable to recover from oxidant damage in the complete absence of 
polymerase activity. 
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1. Introduction 
One of the early reactions in the cell exposed to a 
DNA-damaging agent is activation of a post-translational 
modification enzyme poly(ADP-ribose) polymerase 
(PARP; EC 2.4.2.30). This enzyme, which is present in the 
higher eukaryotic nucleus in great abundance, is activated 
in the presence of DNA strand breaks to utilize NAD and 
form a polymer of ADP-ribose (pADPr) on nuclear accep- 
Abbreviations: DHQ, 1,5-dihydroxyisoquinoline; ‘H-Ade, [2,8- 
‘HlAdenine; IC,, , concentration of the compound to obtain 50% inhibi- 
tion; pADPr, poly(ADP-ribose); PARP, poly(ADP-ribose) polymerase; 
PD 128763, 3,4-dihydro-5-methyl-1(2H)-isoquinoline; “P-NAD, 
[adenylate-“PINAD; RAdo, ribosyladenosine; RCFA, relative colony 
forming ability; TCA. trichloroacetic acid; X/X0, xanthine/xanthine 
oxidase. 
* Corresponding author. Fax: + 1 (418) 654-2761. 
tor molecules such as histones, topoisomerase, and pre- 
dominantly on itself. The polymerase is implicated in a 
variety of cellular responses after DNA damage by oxi- 
dants, ranging from cell survival after sublethal damage or 
cell death after extensive damage [l-3]. The role of PARP 
has been demonstrated in processes that influence cell 
survival after DNA damage, such as DNA repair [4-81 or 
expression of growth-related protooncogene c-fos [9- 111. 
The depletion of cellular NAD pool by massive activation 
of PARP has been considered a cause of metabolic cell 
death 1121. The recent discovery of proteolytic cleavage of 
PARP by a protease resembling interleukin- 1 P-converting 
enzyme (prICE) among the early apoptotic events suggests 
another route through which PARP could be involved in 
cell death [13,14]. 
The essential role of PARP in cellular recovery after 
sublethal oxidant damage has not been conclusively estab- 
lished because chemical inhibitors of PARP, such as ben- 
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zamides, cannot significantly decrease cell survival after 
oxidant damage [15,161. Benzamides are also incomplete 
inhibitors of induction of c-j&s in cells responding to DNA 
damage by oxidant [9] and other genotoxic agents (Shah, 
unpublished data). Similarly, benzamides cannot inhibit 
DNA base excision repair processes in vitro [6]. These 
observations could be correlated to the fact that benza- 
mides are incomplete inhibitors of PARP activity either in 
vitro [17] or in cells exposed to DNA-damaging agents 
[I 5,181. In view of the great abundance of PARP, 80 to 
90% inhibition in its activity obtained by benzamides may 
slow down the cellular functions dependent on PARP by 
making it a rate-limiting step [19], but it would not trans- 
late into complete inhibition of DNA repair or cellular 
recovery. This is evident in mutant cell lines, with reduced 
PARP activity being only marginally more susceptible to 
DNA damage [20] or having a delay in DNA-repair activ- 
ity but not an effective inhibition [8]. In contrast, the use of 
benzamides demonstrated involvement of PARP in cell 
death after toxic oxidant exposure in different types of 
cells, such as fibroblasts, macrophages, or lymphocytes 
[21-231. The protection provided by benzamides was at- 
tributed to a reduction in the activity of PARP, resulting in 
conservation of the NAD, glutathione, and ATP pools. 
Therefore, use of an inhibitor that could completely 
prevent PARP activity at noncytotoxic concentrations 
would clarify the role of PARP in DNA repair and other 
cellular processes. An exhaustive survey of chemicals for 
their capacity to inhibit PARP activity in vitro was re- 
cently carried out in an effort to find more potent and 
specific inhibitors of PARP [ 171. We selected 1,5-dihy- 
droxyisoquinoline (DHQ), one of the three potent PARP 
inhibitors listed in that study, which has a very low IC,, of 
0.39 PM toward PARP and a very high IC,, of 890 PM 
toward mono(ADP-ribosyl) transferase. DHQ was also the 
only inhibitor to produce 100% inhibition of PARP activ- 
ity in vitro at a I-mM concentration [ 171 and, of these 
three inhibitors, it was the least cytotoxic to C3HlOTl/2 
cells (unpublished data). Moreover, a similar compound, 
PD 128763 (3,4-dihydro-5-methyl-1(2H)-isoquinolinone) 
inhibited the recovery of cells after exposure to X-rays [24] 
or monofunctional alkylating agent [25]. We present here 
evidence that cellular recovery after oxidant damage was 
abolished only when there was a complete inhibition of 
PARP activity by DHQ. 
2. Materials and methods 
Mouse embryo fibroblast cells C3HlOT1/2 (clone 8), 
obtained from American Type Culture Collection (Rock- 
ville, MD), were cultured in Eagle’s basal medium (Gibco, 
Burlington, Ont, Canada) supplemented with 8% fetal 
bovine serum (HyClone Laboratories, Logan, UT), at 37°C 
in a humidified CO, (5%) incubator and used between 
passages 9 and 14. 
DHQ was from Aldrich (Milwaukee, WI) and 3- 
aminobenzamide, benzamide, xanthine (X), and xanthine 
oxidase (X0; 1.2 U/mg) were from Sigma (St. Louis, 
MO). The solvent DMSO, used for preparing DHQ solu- 
tions, was kept below 0.5% or 1.4% (v/v) for the in vivo 
or in vitro assays, respectively. [Adenylate- 32 PINAD (32P- 
NAD; 30 Ci/mmol) was purchased from NEN (Missis- 
sauga, Ont., Canada), and [2,8-3H]adenine (3H-Ade; 30 
Ci/mmol) was from ICN (Montreal, Quebec, Canada). 
The high performance liquid chromatography (HPLC) sys- 
tem, i.e., columns, pump, detectors and System Gold 
software for data collection and analysis were from Beck- 
man (Berkeley, CA). 
2.1. In vitro assays of PARP activity 
2.1.1. Enzymatic assay for acid-insoluble pADPrformed in 
citro 
Inhibitory potential of DHQ was analyzed in the in vitro 
assay for PARP (1350 U/mg), purified up to hydroxy- 
apatite step [26,27]. In a total reaction mixture of 140 ~1, 
the inhibitor was incubated at 25°C for 5 min in the 
presence of 100 mM Tris-HCl, pH 8.0; 10 mM MgCl,; 
10% glycerol; 1.5 mM dithiothreitol; 200 PM 32P-NAD 
(specific activity, 18 mCi/mmol); 10 pg activated DNA; 
10 pg total histones. The reaction was carried out with 0.2 
U of PARP at 25°C for 2 min and stopped with 100 ~1 of 
ice-cold 50% trichloroacetic acid (TCA) after the addition 
of 0.5 mg bovine serum albumin. The TCA-insoluble 
precipitate containing 32P-pAPDr was collected on GF/C 
glass fibre filters, washed thoroughly with ethanol, dried, 
and counted for radioactivity [26]. 
2.1.2. Activity blot assay of PARP in vitro 
The ability of DHQ to suppress the activity of PARP 
was also assayed by the activity blot technique according 
to Shah et al. [26]. Samples were electrophoresed on a 
sodium dodecyl sulfate/polyacrylamide minigel (8% 
w/v), and the gels were soaked at 37°C in 0.7 M @-mer- 
captoethanol; 190 mM glycine; 25 mM Tris-HCl, pH 8.0; 
and 0.1% sodium dodecyl sulfate, before electrotransfer on 
a nitrocellulose membrane. The enzymatic activity of PARP 
was detected by its ability to synthesize 32P-pADPr from 
the substrate 32 P-NAD, as described earlier [28,29]. Nitro- 
cellulose membranes were soaked for 1 h in 10 ml of 
renaturation buffer (50 mM Tris-HCl, pH 8.0; 100 mM 
NaCl; 1 mM dithiothreitol; 0.3% Tween 20) containing 2 
pg/ml activated DNA, 20 PM Zn(I1) acetate, and 2 mM 
MgCl,. When required, the blots were incubated with the 
inhibitor for 15 min in the renaturation buffer. The enzy- 
matic activity was carried out for 1 h with 2 pCi/ml of 
32 P-NAD. Unprocessed 32P-NAD was removed by four 
washes for 15 min with 20 ml of renaturation buffer. The 
blots were dried and analyzed by autoradiography using 
Kodak X-OMAT AR5 films to visualize the labeled, auto- 
modified PARP. 
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2.2. Analysis of pADPr and NAD levels in cells 
C3HlOT1/2 cells were labeled with 3H-Ade, which is 
incorporated in the NAD pool, and oxidant-induced 3H- 
pADPr synthesized in these cells was isolated and ana- 
lyzed as 3H-ribosyladenosine (RAdo) [26,301. Confluent 
monolayers of C3HlOT1/2 cells were incubated in 5 ml 
of complete medium containing 20 &i/ml of 3H-Ade for 
16 h. The cells were incubated with DHQ for 1 h before 
exposure to X/X0 (lOO/lO pg/ml for 30 min) in the 
serum-free medium. The cells were washed twice with 
cold phosphate buffered saline and harvested with 2 X 1 
ml 20% TCA (4°C) for 15 min at 4°C. The TCA pellet was 
collected at 1000 X g for 10 min at 4°C and processed for 
pAPDr analysis [26]. Specific activity of NAD pool in the 
TCA supernatant was analyzed after purification through 
dihydroxyboronyl Bio-Rex (DHBB) chromatography fol- 
lowed by a cycling microassay for NAD as recently de- 
scribed by us [26]. 
The protein-bound 3H-pADPr in the TCA pellet was 
dissolved in formic acid, and precipitated with 20% TCA 
(4°C 15 min) after the addition of 1 mg bovine serum 
albumin and a spike of 1 nmol of cold pADPr. After 
centrifugation for 10 min at 1000 X g and 4°C the TCA- 
insoluble pellet was processed further to isolate and ana- 
lyze pADPr essentially as described by Shah et al. [26]. In 
brief, 3H-pADPr was separated from the proteins by diges- 
tion at 37°C for 2 h with 1 M KOH, 50 mM EDTA, and 
purified by dihydroxyboronyl BioRex (DHBB) chromatog- 
raphy. The ‘H-pADPr preparation was digested at 37°C for 
2 h with 25 U of RNase A to remove any contaminating 
RNA. It was then digested at 37°C overnight with 0.25 U 
of snake venom phosphodiesterase and 2.5 U of bacterial 
alkaline phosphatase to form ‘H-RAdo or diribosyladeno- 
sine. 3H-RAdo was resolved from other nucleosides by 
HPLC [31] on a C,, reverse-phase column (5 pm, 4.6 X 
150 mm) isocratically eluted at 30°C at 1 ml/min with 7 
mM ammonium formate, pH 5.8, containing 6% methanol. 
After UV detection at 254 nm, radioactivity in the effluent 
was monitored by an on-line detector after mixing with 4 
volumes of PCS liquid scintillation cocktail (Amersham, 
Oakville, Ont., Canada). The retention times of Ado, dAdo, 
and RAdo were 22, 26, and 32 min, respectively [26]. The 
endogenous RAdo was estimated from radioactivity pre- 
sent in the RAdo peak and from the specific activity of the 
3H-NAD pool in the cells. Our improvements [26] over the 
original technique 1311 enabled us to detect small quanti- 
ties of pADPr formed in the control samples. 
2.3. Assay of clonogenicity 
Cell survival after oxidant exposure was measured by 
the standard clonogenic assays [32]. In brief, the cells were 
incubated in complete medium for 16 h with DHQ or 
solvent DMSO and exposed for 30 min to X/X0 (lOO/ 10 
pg/ml) in the presence of DHQ in serum-free medium. 
The cells were allowed to recover for 24 h in complete 
medium containing the inhibitor, rinsed with phosphate 
buffered saline, trypsinized, counted, and redistributed in 
60-mm petri dishes in triplicate. Plating efficiency was 
determined as the percentage of the seeded cells that 
formed colonies after 10 days. The relative colony-forming 
ability (% RCFA) was calculated from the plating effi- 
ciency of treated cells compared with control cells [32]. 
3. Results 
3. I. DHQ, a potent inhibitor of PARP actiuity in vitro 
We observed that DHQ (IC,,: N 0.3 PM) was at least 
30-fold more effective in inhibiting PARP activity in vitro 
than benzamide (Fig. 1). As our interest was in total 
inhibition of PARP activity, the data for reduction of 
PARP activity at low concentrations ( < 10 PM) of benza- 
mide are not presented here. Furthermore, a complete 
inhibitory profile of benzamide has been characterized by 
Rankin et al. [19]. The inhibition observed with 100 PM 
DHQ was more complete than that with 1 mM benzamide 
(Fig. 1). This finding was further confirmed in the activity 
blot assay of PARP (Fig. 2). The amount of radioactivity 
present at * 116 kDa reflects the activity of PARP result- 
ing in its automodification with 32P-pADPr (Fig. 2, lane 
1). Nearly complete inhibition of PARP activity was ob- 
served at 10 to 100 PM DHQ compared with 500 to 1000 
PM 3-aminobenzamide required for a similar effect (Fig. 
2, lanes 8 and 9 compared with lanes 4 and 5). Thus, DHQ 
was at least 10 to 50 times more potent an inhibitor of 
PARP activity compared with 3-aminobenzamide. 
3.2. DHQ inhibits oxidant-induced pADPr synthesis in 
intact cells 
We previously observed that 1 mM benzamide was 
unable to inhibit completely the accumulation of pADPr in 
C3HlOTl/2 cells exposed to an oxidant [15,33]. There- 
fore, the potency of DHQ to inhibit oxidant-induced pADPr 
synthesis was tested in these cells (Fig. 3). The pADPr 
levels, which were very low in control cells (N 7 pmol 
RAdo /lOa cells), increased 115-fold on exposure to 
X/X0. Treatment of cells at 0.01 and 0.1 mM DHQ 
brought about 95 and 98% reductions in oxidant-induced 
pADPr levels, respectively. Although these are significant 
decreases, the pADPr levels in cells treated with 0.1 mM 
DHQ were still 1.7-fold greater than in the controls. The 
oxidant-induced pADPr levels were totally suppressed 
(60% of control) only at 1 mM DHQ. Basal polymer 
synthesis was not affected by 1 mM DHQ. A similar 
inhibitory profile of DHQ was observed with H,O,-in- 
duced pADPr synthesis in these cells (data not shown), 
indicating the effectiveness of DHQ in inhibiting oxidant- 
induced pADPr synthesis. 
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3.3. Total inhibition of pADPr synthesis preuents recovery 
qf cells after oxidant exposure 
Our previous studies demonstrated benzamides to be 
incapable of reducing the viability of oxidant-exposed 
C3HlOT1/2 cells [ 151. Therefore, the inhibitory capacity 
of DHQ on the plating efficiency of these cells after 
oxidant damage was analyzed (Fig. 4). Exposure to X/X0 
per se decreased the RCFA to 40% of control values (Fig. 
4A,B). Additional exposure to 0.0 1 or 0.1 mM DHQ could 
not decrease the RCFA as significantly (Fig. 4C,D) as the 
drop in pADPr level (Fig. 3). In contrast, cellular recovery 
from oxidant shock was almost completely inhibited by 1 
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Fig. I. Effect of DHQ and benzamide on PARP activity in vitro was 
assayed by its ability to incorporate “P-NAD into ” P-pADPr in the 
presence of activated DNA. The reaction was terminated by TCA, and the 
acid-insoluble ‘* P-pADPr was harvested on GF/C glass fibre filters and 
counted for radioactivity. PARP activity in the absence of any inhibitor 
(solvent control) was 27.9+ 1.3 (mean+S.D.; n = 6; considered 100% 
PARP activity) pmol ‘* P-NAD incorporated in TCA-insoluble precipitate 
under standard assay conditions. The inhibitors were preincubated for 5 
min before addition of the enzyme. Effect of inhibitor on PARP activity 
is expressed as percentage of controls and values are mean + S.D. of four 
independent experiments. 
3-AB (PM) DHQ (PM) 
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Fig. 2. Inhibition of pADPr synthesis by DHQ and 3-aminobenzamide 
(3-AB) was measured in the activity blot. An identical amount of purified 
PARP (100 “g/lane) was electrophoresed and transferred onto a nitro- 
cellulose membrane. Each lane was separately renatured after preincuba- 
tion with specified concentration of the inhibitor, and the activity of 
PARP was detected by automodification with “P-pADPr formed from 
“P-NAD. The activity of renatured PARP in the absence of inhibitors 
can be seen in the control (lane # 1) at M, 4 I16 kDd. This experiment is 
representative of an experiment done twice. 
cytotoxicity of the inhibitor, as there was only - 20% 
reduction in RCFA at 1 mM DHQ with no significant 
effect on RCFA below I-mM concentrations (Fig. 4F-H). 
The lack of toxic effect of DHQ in these cells was further 
confirmed because the control cells exposed to 1 mM 
DHQ for 16 h, exhibited a transient decrease in metabolic 
activity, measured by the tetrazolium-based calorimetric 
assay [34], but there was no significant change in the 
proportion of cells in each phase of the cell cycle up to 48 
h after exposure to the inhibitor (data not shown). 
4. Discussion 
The inability of benzamides to reduce the viability of 
oxidant-exposed fibroblasts [ 151 does not correspond with 
the role of PARP in processes that influence cell survival, 
such as DNA repair. However, because of the great abun- 
dance of PARP in the nucleus, its incomplete inhibitors, 
such as benzamides, would allow residual activity of PARP, 
which may be sufficient for most cellular functions. We 
clearly show here that a very low level (l-5%) of PARP 
activity would be sufficient to allow the cell to recover 
from sublethal oxidative damage (Figs. 3 and 4). We also 
demonstrate that cellular recovery is completely abolished 
only when PARP activity is totally inhibited. It was esti- 
mated that even minor automodification i.e., 2-3 ADP- 
ribose residues per modification site would prevent PARP 
from reattaching to DNA and render it incapable of block- 
ing DNA repair [6]. This is reflected in the continuation of 
DNA repair [6] or cellular survival after oxidant damage 
[15] in the presence of low-level PARP activity. In con- 
trast, DHQ can abolish cellular recovery after oxidant 
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damage, and we suggest that this may arise from its 
capacity to completely block the role of PARP in DNA 
repair. 
PARP may also be a major participant in other cellular 
recovery processes downstream from DNA repair, for 
example, activation of growth-related proto-oncogenes c- 
fos or c-myc [35]. In mouse epidermal fibroblasts, through 
the use of benzamides, the induction of c-f& after direct or 
indirect oxidative damage was shown to be partially de- 
pendent on PARP [9,10]. The potent inhibitor DHQ may 
inhibit the activation of these genes, as observed with 
inhibitors of protein kinase C [9,10]. As expression of 
these genes is linked to cellular recovery and growth, the 
lack of cell survival in the total absence of PARP activity 
may arise from the role of PARP in activation of these 
genes. 
Different studies [24,25,37,38] carried out with DHQ or 
PD128763 (which is also an isoquinoline) indicate an 
absence of nonspecific side effects, such as an alteration in 
nucleotide metabolism, observed for benzamides [36]. This 
is the first report on the effects of DHQ on pADPr 
metabolism in mouse embryo fibroblasts and its subse- 
quent effects on cell survival. Other studies have reported 
that DHQ-mediated inhibition of PARP results in reduced 
nitric oxide toxicity in neuronal cells [37] or increased 
antibody class switching in B cell lymphomas [38]. No 
toxicity has been reported for PD 128763, an isoquinoline 
compound similar to DHQ, during studies with L1210 
cells or Chinese hamster V79 cells (24,251. Also, we did 
not observe any DHQ cytotoxicity in mice, fish, or differ- 
ent cultured cell lines at concentrations that are effective in 
inhibiting pADPr synthesis. The possible noncytotoxic ef- 
fect of DHQ on other cellular processes or enzymes that 
affect cell survival, however, needs to be explored. 
Oxidant-mediated cell death is believed to involve the 
activation of PARP, resulting in the depletion of NAD and 
ATP or glutathione pools of the cell [22,23]. 1 mM DHQ 
did not affect NAD, NADP or ATP pools, however glu- 
XJXO x/x0+ x/x0+ x/x0+ 
0.01 mM O.lmM 1mM 
DkK2 DI-KJ 0l-D 
Treatment Groups 
Fig. 3. Inhibition of oxidant-induced pADPr synthesis in C3HlOT1/2 cells by DHQ. Synthesis of ‘H-pADPr was induced by treatment with X/X0 
(lOO/lO yg/ml for 30 min) in ‘H-Ade labeled cells as described in Materials and Methods. The cells were incubated with DHQ or the solvent for 1 h 
before exposure to the oxidant. The purified pADPr was digested to RAdo, which was separated on HPLC and analyzed by an on-line radioactivity 
detector. Aliquots representing - 2.5 lo6 cells were analyzed for samples with low pADPr levels. The values of RAdo presented are mean + S.D. from 
the duplicate analysis from two separate experiments. 
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tathione pools were increased thus suggesting more antiox- 
idant defense. Therefore, a 90 to 95% inhibition in PARP 
activity by benzamides could significantly reduce cell 
killing by toxic concentrations of oxidant. At sublethal 
concentrations of oxidants used in these studies, DHQ did 
not protect the cells from oxidant damage, because 95 to 
98% reduction in PARP activity could not significantly 
increase the RCFA (Figs. 3 and 4). Therefore, the cell 
death observed at 1 mM DHQ, as a result of the potentia- 
tion of oxidant damage, occurs in the absence of PARP- 
mediated repair pathways such as those happening in base 
excision repair (4,5) and thus does not appear to be caused 
by a decrease of ATP, NAD, NADP, or glutathione pools. 
In the absence of inhibitor during the last 10 days of the 
survival assay, normal PARP activity is expected in the 
phase during which the cells either die or recover to form 
colonies. 
Inhibitors of PARP have varying effects on different 
cells because of differences in effective intracellular con- 
centrations of the inhibitor [ 19,2 1,361. These variations can 
be further influenced during oxidant damage by the pres- 
ence of other factors involved in antioxidant defense in the 
cell [22]. Thus, 10 /.LM of DHQ could be effective in 
inhibiting nitric oxide-mediated neurotoxicity [37], whereas 
0.5 to 1 mM of DHQ or related compounds are needed to 
inhibit the recovery of Chinese hamster V79 or L12 10 
cells after damage by X-rays or alkylating agents [24,25] 
or of C3HlOT1/2 cells after oxidant damage, as shown 
here. 
In this study, we demonstrated that complete inhibition 
of PARP activity by DHQ reveals the role of PARP in 
cellular recovery after oxidant damage. The recovery of 
cells in presence of even a minor fraction of the PARP 
activity should be carefully considered while studying 
PARP by other approaches, such as trans-dominant inhibi- 
tion or mutant cell lines with reduced PARP activity. More 
studies with DHQ in processes such as apoptosis, DNA 
repair, or recombination and in cellular survival after 
different types of DNA damage could help define the role 
of PARP in these cellular processes. 
G 
Control XIX0 x/x0 + x/x0+ x/x0+ 0.Olmh-l O.lmM 1mM DHQ 
0.01 mM O.lmM 1mM DHQ DHQ DHQ 
DHQ DHQ 
Treatment Groups 
Fig. 4. Effect of DHQ on clonogenicity of C3HlOTl/2 cells exposed to oxidants. Plating efficiency, that is, the % of cells seeded that form colonies, was 
measured after treatment with oxidant (X/X0) and/or DHQ. The effect of the inhibitor was expressed as relative colony forming ability (RCFA), i.e., 
plating efficiency of experimental group as % of DMSO-treated control, which was 27 f 3 (mean & SD.; n = 6, 100% RCFA). In two separate 
experiments, cells for each treatment group were plated in triplicate, at high and low cell densities to obtain accurate count of plating efficiency even at 
higher concentration of the inhibitors. Results (mean * S.D., n = 6) are expressed as RCFA (8 control). 
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